Search
Close this search box.

Massive Bio, Mika Health Blend AI with Digital Therapy to Boost Cancer Trial Access

The partnership aims to streamline clinical trial enrollment, reduce manual effort, and ultimately improve treatment options and outcomes through data-driven insights into patient experiences and real-world evidence.

Massive Bio and Mika Health, two leading AI-enabled healthcare technology companies, announced a partnership aimed at enhancing access to clinical trials, biomarker testing, and digital therapeutics for cancer patients.

The collaboration will allow patients receiving treatment through Mika Health’s personalized oncology digital therapeutic platform to opt into Massive Bio’s AI-powered clinical trial matching system and next-generation sequencing (NGS) biomarker testing eligibility engine. Conversely, Massive Bio will provide free access to Mika Health’s digital therapy to its registry of hundreds of thousands of cancer patients.

“Patients waiting to find and access effective cancer treatments face tremendous challenges, both physical and mental,” said Dr. Gandolf Finke, CEO and Founder of Mika Health. “Our partnership with Massive Bio will help more patients access genomic testing, get matched to suitable clinical trials faster, and receive essential psycho-oncological support – ultimately improving outcomes and experiences.”

Despite evidence showing the benefits of NGS biomarker testing in dictating cancer survivorship, its utilization remains low, with less than 50% of eligible lung cancer patients receiving the standard-of-care testing in the U.S. and Europe.

“By combining our AI expertise with Mika Health’s comprehensive digital therapy, we can significantly enhance cancer patient outcomes and access to innovative therapies and much-needed support,” remarked Dr. Selin Kurnaz, Co-Founder and CEO of Massive Bio.

The partnership aims to streamline clinical trial enrollment, reduce manual effort, and ultimately improve treatment options and outcomes through data-driven insights into patient experiences and real-world evidence.

“Integrating our platforms will empower patients and oncologists with the support patients desperately need as they seek personalized and accessible treatments,” said Dr. Arturo Loaiza-Bonilla, Co-Founder and Chief Medical Officer of Massive Bio. “It will also expand awareness and utilization of biomarker and genomic testing when appropriate.”

As cancer treatments become more personalized, this collaboration between Mika Health and Massive Bio positions itself as a crucial step toward closing the access gap, raising the standard of care quality, and accelerating time to the right treatment for patients.

Picture of Mansi Singh
Mansi Singh
Mansi is an Associate Content Strategist. She holds interest that centers around use of Gen AI in enhancing daily lives and she is dedicated to exploring the latest trends and tools in AI. She can be reached at mansi.singh@aimresearch.co
Subscribe to our Latest Insights
By clicking the “Continue” button, you are agreeing to the AIM Media Terms of Use and Privacy Policy.
Recognitions & Lists
Discover, Apply, and Contribute on Noteworthy Awards and Surveys from AIM
AIM Leaders Council
An invitation-only forum of senior executives in the Data Science and AI industry.
Stay Current with our In-Depth Insights
The Biggest Exclusive Gathering Of CDOs & Analytics Leaders In United States

MachineCon 2024
26 July 2024, New York

MachineCon 2024
Meet 100 Most Influential AI Leaders in USA
Our Latest Reports on AI Industry
Supercharge your top goals and objectives to reach new heights of success!

Cutting Edge Analysis and Trends for USA's AI Industry

Subscribe to our Newsletter